Opinion: The smart way to regulate the peptide boom

OpinionFirst Opinion The smart way to regulate the peptide boom The FDA should take a middle-ground approach instead of outright banning popular but unproven peptides Manage alerts for this article Email this article Share this article By Jerome AdamsJuly 6, 2026 Adams served as the 20th surgeon general of the United States. Americans are using peptide compounds (short chains of amino acids promoted for recovery, sleep, performance, metabolic health, and longevity) in large and growing numbers. Many obtain them from unregulated online sellers and informal markets, often without medical supervision, reliable quality controls, or accurate dosing information. Whether we like it or not, this is a mainstream reality, and it creates the very risks regulators seek to avoid. With Kyle Diamantas now at the helm of the Food and Drug Administration as acting commissioner, the agency has a timely opportunity. Rather than choosing between unrestricted gray-market access or a blanket crackdown that simply drives use underground, the agency can chart a third way on peptides. Advertisement The Pharmacy Compounding Advisory Committee meets July 23-24 to consider restoring certain peptides to the list of substances eligible for compounding by licensed 503A pharmacies, with a follow-up meeting to be held before February 2027. At that meeting, the FDA should pursue a structured, clinician-guided framework that brings existing demand under professional oversight while maintaining rigorous safety, quality, and research standards. Peptides are not monolithic. Some, like insulin and GLP-1 agonists such as semaglutide, are among the most transformative medicines of our era. They are rigorously tested, FDA-approved, and safely prescribed daily. Others, promoted for wellness and performance, currently lack the same level of evidence and regulatory scrutiny. These compounds now operate in a dangerous gray zone: labeled “research use only” or “not for human consumption,” sourced without consistent quality assurance, and used without clinical guidance. Simply restricting all access to these gray-zone peptides does not eliminate demand. History shows prohibition-style approaches to substances with perceived benefits push consumers toward riskier, unregulated channels. The greatest public health danger today lies not in medically supervised use, but in these unchecked black and gray markets.Advertisement The smarter path is a practical middle ground: create a way for selected, widely used peptides to be made available under strict oversight by licensed pharmacies that meet federal and state quality, sourcing, and sterility standards. Patients would access them only through a licensed clinician who: evaluates the individual patient’s needs and risks using professional judgment; provides clear, balanced information on what is known and not yet known from available studies, animal data, and real-world use; and ensures ongoing monitoring and reporting of outcomes. This framework should not and would not replace full FDA approval pathways, nor suggest that compounded versions equal rigorously tested, manufactured drugs. It would simply recognize reality and channel it toward safer, more transparent practices. Compounded medications would need to carry explicit disclaimers, and clinicians would document informed patient decisions. Such a system delivers multiple benefits. First, it reduces immediate harm by replacing rogue online products with quality-controlled ones. Second, it generates real-world evidence: Structured oversight and outcome tracking can help build the safety and efficacy data these compounds currently lack. Third, it respects patient autonomy while restoring the role of clinicians as guides rather than bystanders. Many patients already arrive at doctors’ offices asking about peptides they discovered on social media or wellness sites. Providers need better tools and guidance to respond effectively. The potential upside is meaningful. For Americans struggling with poor recovery, sleep disruption, metabolic issues, or age-related decline, clinician-supervised peptides might offer genuine benefits (if we study and regulate their use intelligently instead of pretending the demand will vanish). Diamantas and the FDA should seize this moment, and the July PCAC meeting is an ideal starting point. The agency can provide clearer public information regarding peptides placed on the bulks list, support clinician education, and establish transparent labeling and safety data collection requirements for compounded versions.Advertisement We do not need to abandon scientific rigor. We need to apply it more pragmatically to how care is actually being sought and delivered in 2026. A structured, clinician-guided third way protects patients today, gathers evidence for tomorrow, and prevents the worst outcomes of an unregulated boom. The FDA has the authority and the opportunity to lead. It should use both. Jerome M. Adams, M.D., M.P.H., served as the 20th surgeon general of the United States. Letter to the editor Have an opinion on this essay? Submit a letter to the editor. FDA, Pharmaceuticals, Policy Submit a correction requestReprints Jerome Adams Newsletter The smartest thinkers in life sciences on what's happening — and what's to come Recommended First Opinion July 6, 2026 Stopping doctors from ordering unnecessary diagnostic tests requires a structural fix First Opinion July 2, 2026 CDC leadership continues to try to manufacture a scientific debate on vaccines where none exists Advertisement First Opinion July 2, 2026 Teens are turning to chatbots for mental health help. We need rules to keep them safe First Opinion July 1, 2026 Maryland Gov. Wes Moore: How to improve young men’s mental health First Opinion July 1, 2026 What Ebola and Marburg are teaching us about the next pandemic Subscriber Picks